Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


      © 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Citalopram hydrobromide

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Citalopram Hbr Manufacturers in India Suppliers Citalopram Hbr Exporters Distributors Citalopram Hbr api active pharmaceuticals ingredients Citalopram Hbr manufacturers Side Effects bulk drugs raw material Citalopram Hbr companies Side Effects Importers Citalopram Hbr Citalopram Hbr Exporters Citalopram Hbr exporters FDA Citalopram Hbr DMF Symptoms Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Citalopram Hydrobromide manufacturing pharmaceutical drugs pharmaceutical intermediates Citalopram Hydrobromide pharmaceutical chemicals pharmaceutical raw materials Citalopram Hydrobromide active pharmaceutical ingredients Citalopram Hydrobromide committee active pharmaceutical ingredients manufacturer Citalopram Hydrobromide Active Pharmaceutical Ingredients manufacturer Citalopram Hydrobromide exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Citalopram Hbr, Citalopram Hbr manufacturer India, Citalopram Hbr product, Citalopram Hbr products, Api preparation, Certificate of Analysis API manufacturer product, Citalopram Hbr anti ulcer product, Certificate of Origin COA Citalopram Hbr COS Citalopram Hbr, pharmaceutical generic, pharmaceutical drug, medical, Citalopram Hbr pharma healthcare, pharma patents, contract MSDS manufacturing Trader Citalopram Hbr pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Citalopram Hbr expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Citalopram Hbr DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Citalopram Hbr ingredients, api, HIV Citalopram Hbr, tablets, capsules, syrup & protein Citalopram Hbr powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Citalopram Hbr gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Citalopram Hbr WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

Citalopram hydrobromide











 




 







 

 

HOME >> API >> API List1 >> Citalopram Hbr >> Pharmalogy

 Citalopram hydrobromide CAS Registry Number 59729-32-7

PHARMALOGY
Citalopram hydrobromide CAS Number 59729-32-7

The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT). In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake. Tolerance to the inhibition of 5-HT uptake is not induced by long-term (14-day) treatment of rats with citalopram. Citalopram is a racemic mixture (50/50), and the inhibition of 5-HT reuptake by citalopram is primarily due to the (S)-enantiomer.

Citalopram has no or very low affinity for 5-HT1A, 5-HT2A, dopamine D1 and D2, α1-, α2-, and β­adrenergic, histamine H1, gamma aminobutyric acid (GABA), muscarinic cholinergic, and benzodiazepine receptors. Antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of other psychotropic drugs.
The single- and multiple-dose pharmacokinetics of citalopram are linear and dose-proportional in a dose range of 10-60 mg/day. Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours. With once daily dosing, steady state plasma concentrations are achieved within approximately one week. At steady state, the extent of accumulation of citalopram in plasma, based on the half-life, is expected to be 2.5 times the plasma concentrations observed after a single dose. The tablet and oral solution dosage forms of citalopram HBr are bioequivalent.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE
SIDE EFFECTS
PRECAUTIONS
INTERACTION
PHARMALOGY >>
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Citalopram Hbr

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium

Clonazepam

Amitriptyline

Clopidogrel Bisulfate

Anastrozole

Danazol

Atomoxetine Hcl

Desloratadine

Balsalazide

Desmopressin Monoacetate

Bicalutamide

Divalproex Sodium

Budesonide

Dobutamine Hcl

Bupropion Hcl

Donepezil

Calcitonin

Dothiepin Hcl

Capecitabine

Entacapone

Carbamazepine

Eptifibatide

Carboplatin

Escitalopram HBr

Carisoprodol

Eszopiclone

Carvedilol

Finasteride

Cefuroxime Axetil

Flurbiprofen

Cisplatin

Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Copyright © Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap

 

taj group logo
© 2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals  Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals  Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.